Glenmark Pharma reports consolidated revenue growth of 6.3% and adjusted EBITDA growth of 8.3% YoY for Q2 FY 2023-24
Highlights for Q2 FY 2023-24 Europe Business grew by 58.4% to Rs. 5,997 Mn. RoW Business grew by 19% to Rs. 7,324 Mn. India Business grew by 2.8% to Rs. 11,217 Mn. North America Business declined
Read More